AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
ResMed Navigates International Trade Policy with Tariff Exemption
April 24, 2025 01:30 PM AEST| By Team Kalkine MediaHighlights:,ResMed (ASX:RMD) secured a tariff exemption from the U.S. for products shipped from Australia and Singapore.,The exemption is tied to the Nairobi Protocol, which supports trade in products aiding individuals with disabilities.,Broader unc...
ResMed Soars on Robust Q3 Performance, Driven by Strong Product Demand and Margin Growth
April 24, 2025 11:39 AM AEST| By Team Kalkine MediaHighlights,ResMed reports 21% surge in quarterly earnings,Revenue hits US$1.29 billion on rising demand for sleep health devices,Gross margin expands to 59.3% on product mix and operational efficiency,ResMed (ASX:RMD) shares climbed over 8% to $35.99...
ResMed Secures Tariff Exemption, Boosts US Presence Amid Trade Tensions
April 24, 2025 10:53 AM AEST| By Team Kalkine MediaHighlights,ResMed receives exemption from US trade tariffs,Expands US manufacturing to manage policy uncertainty,Q3 revenue grows 8% to $US1.3 billion,Global sleep technology company ResMed (ASX:RMD) has announced that its products manufactured in Au...
Telix Pharmaceuticals Drives Growth Surge Among ASX Healthcare Stocks
April 23, 2025 04:55 PM AEST| By Team Kalkine MediaHighlights:,Telix Pharmaceuticals has expanded its revenues significantly within a few years, marking a sharp rise in commercial success.,The company has progressed from regulatory approvals to successful diagnostic and therapeutic product rollouts.,...
Cochlear Limited (ASX:COH) Navigates Market Pressures with Long-Term Resilience
April 23, 2025 04:33 PM AEST| By Team Kalkine MediaHighlights,Cochlear shares have declined in the recent quarter but maintain notable growth over an extended period,Shareholder return outpaces stock price gains due to consistent dividend contributions,Company records multiple senior-level stock acqu...
NeuroScientific Biopharmaceuticals (ASX:NSB) Shares Advance as Market Reassesses Valuation
April 23, 2025 04:32 PM AEST| By Team Kalkine MediaHighlights,NeuroScientific Biopharmaceuticals Limited stock price rose significantly over the past month,Company’s valuation remains below broader market averages based on earnings multiples,Earnings have improved recently, though longer-term trends...
We Are Monitoring Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate
April 23, 2025 04:32 PM AEST| By Team Kalkine MediaHighlights,Paradigm Biopharmaceuticals reported a significant year-on-year reduction in cash usage,Cash reserves remain above spending levels, offering a manageable funding horizon,Future capital requirements could lead to shareholder dilution if equ...
If you had invested in Ansell (ASX:ANN) a year ago, you would have achieved a 13% gain.
April 23, 2025 04:30 PM AEST| By Team Kalkine MediaHighlights,Ansell shares declined in the recent quarter but recorded year-on-year gains.,Revenue growth surpassed earnings performance over the last twelve months.,Total shareholder return outpaced share price movement due to dividend contributions.,...
FDA Clearance Drives Orthocell (ASX:OCC) Momentum Among ASX Healthcare Stocks
April 23, 2025 04:04 PM AEST| By Team Kalkine MediaHighlights:,Orthocell announces distributor agreements across key US regions for its flagship medical product,FDA clearance enables immediate commercial rollout in the US healthcare market,Remplir collagen wrap to be promoted by regional specialists...
Lumos Diagnostics (ASX:LDX) Expands Medicare Coverage for FebriDx Test in the US
April 23, 2025 02:10 PM AEST| By Team Kalkine MediaHighlights,Medicare expansion boosts diagnostic reach,FebriDx now covered by 55% of US Medicare,Lumos eyes full national adoption,Lumos Diagnostics (ASX:LDX) has achieved a major milestone in its US commercialization efforts, securing additional Medi...
Orthocell signs up first four Remplir distributors in the lucrative US market
April 23, 2025 02:08 PM AEST| By Team Kalkine MediaHighlights:,Orthocell appoints four US distributors following recent regulatory approval of its Remplir product.,The company is pursuing broader geographic representation through an expanding distributor network.,Remplir is already available in sever...
Race Oncology Progresses RC220 Clinical Trial and Enhances Profile
April 23, 2025 02:05 PM AEST| By Team Kalkine MediaHighlights:,Race Oncology received ethics and regulatory clearance to initiate its Phase 1 RC220 trial.,Clinical activity began at Southside Cancer Care Centre, with additional trial sites preparing for activation.,The company maintained a robust fin...
Orthocell Taps into Lucrative US Market with Strategic Distributor Rollout for Remplir
April 23, 2025 01:35 PM AEST| By Team Kalkine MediaHighlights,Orthocell expands into the US nerve repair market with four initial distributors,Remplir rollout supported by inventory and efficient distribution model,Targeting further expansion to reach 25 US states by mid-year,Regenerative medicine sp...
Race Oncology Progresses Cancer Drug Trial and Strengthens Financial Footing in March Quarter
April 23, 2025 01:18 PM AEST| By Team Kalkine MediaHighlights,Phase 1 trial for RC220 gains key regulatory approvals,Strong cash reserves to support over two years of operations,Inclusion in All Ordinaries Index underscores market recognition,Race Oncology (ASX:RAC) marked significant progress during...
Why Sonic Healthcare (ASX:SHL) Remains a Standout in a Shifting Market
April 23, 2025 12:10 PM AEST| By Team Kalkine MediaHighlights,SHL shares down 8.5% in 2025 despite long-term growth prospects,Healthcare sector offers stable, recession-resistant revenue streams,Global trends position SHL for sustainable and ethical-focused growth,The share price of Sonic Healthcare...
Orthocell anticipates imminent US Remplir sales after securing a distribution agreement.
April 23, 2025 11:30 AM AEST| By Team Kalkine MediaHighlights,Orthocell expands into U.S. with strategic product distribution agreement,Remplir targets critical need in surgical nerve repair market,Strong financial position supports international growth strategy,The biotechnology sector is currently...
Ansell Delivers 13% Return Over the Year Despite Recent Weakness
April 23, 2025 11:11 AM AEST| By Team Kalkine MediaHighlights,Ansell (ANN) posted a 13% return over the past year,Share price dipped 17% in the last quarter, contrasting long-term gains,Revenue growth and dividends supported positive total returns,Ansell (ASX:ANN) has offered investors a noteworthy r...
Alcidion Group Advances on Market Despite Revenue Decline
April 22, 2025 09:02 PM AEST| By Team Kalkine MediaHighlights,Alcidion Group operates in the health technology sector with a focus on digital healthcare solutions,The company experienced a significant increase in share price over the past year despite a decline in revenue,Longer-term performance rema...
Telix Pharmaceuticals (ASX:TLX) Delivers Strong Q1 Growth with Revenue Surge and Strategic U.S. Expansion
April 22, 2025 07:32 PM AEST| By Team Kalkine MediaHighlights,Telix revenue jumps 62% YoY to $186 million in Q1 2025,Illuccix® sales power growth with $151 million contribution,Strategic RLS acquisition adds $33 million and expands U.S. operations,Telix Pharmaceuticals (ASX:TLX) has kicked off FY 202...
Oversold ASX Healthcare Share Sees Major Drop Despite Strong Business Momentum
April 22, 2025 04:11 PM AEST| By Team Kalkine MediaHighlights:,Healthcare software firm sees significant drop from its yearly peak amid broader tech sector decline,Business maintains strong margins, debt-free status, and continues securing large US contracts,Strategic expansion in artificial intellig...
Advertise your brand on Kalkine Media